MET, the tyrosine kinase receptor of HGF, is another potential target in different types of solid and hematological neoplasms, such as colorectal carcinoma [3], glioblastoma [4,5], and breast carcinoma [6]. The gene discussed is MET; the disease is glioblastoma.